(ha) it must be presented in such a way as to ensure that the dosage of the medicinal product is perfectly understandable, paying particular attention to those medicinal products whose correct administration is complex.

Question No. 609 Ms. Anne Minh-Thu Quach: With respect to drug regulation and approval: (a) does the 2012 Economic Action Plan provide for decreases or increases in the financial and human resources allocated to (i) drug approval services, (ii) regulatory activities to evaluate and monitor the safety, efficacy and quality of drugs before and after they enter the marketplace, (iii) activities related to the review of submissions by drug manufacturers for market authorization and post-market changes, (iv) activities related to enforcing compliance with existing regulations, including those concerning clinical trials, drug manufacturing and ...[+++] the reporting of adverse drug reactions, (v) activities of the Patented Medicine Prices Review Board, (vi) services such as the Patent Register, Drug Product Database, Notice of Compliance, and Progressive Licensing Project, (vii) various areas of Health Canada such as the Marketed Health Products Directorate, Therapeutic Products Directorate, Biologics and Genetic Therapies Directorate, and the Veterinary Drugs Directorate; (b) for each of the programs and directorates listed in (a), (i) what is the estimated extent of the decreases or increases in human or financial resources, (ii) are positions expected to be cut and, if so, how many will be eliminated; (c) was a value-for-money assessment conducted for the drug approval process; and (d) what is the government’s financial allocation plan regarding drug regulation?

‘1. A list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products, designed to amend non-essential elements of this Directive by supplementing it, shall be established in accordance with the regulatory procedure with scrutiny referred to in Article 121(2a). This list shall contain, with regard to each herbal substance, the indication, the specified strength and the posology, the route of administration and any other information necessary for the safe use of the herbal substance as a traditional medicinal product’.

The CMA proposes that the health care system work to create a culture that promotes optimal prescribing by addressing the shortage of qualified health professionals, by closing the knowledge gap on drug utilization patterns, by creating and adequately funding a safety infrastructure, by strengthening post-marketing surveillance, by investing in supportive technology, and by enhancing privacy protection for patients and prescribers.

Changes in the cost of drugs are affected not only by price but, as you've heard from Ms. Ouellet, by utilization the number of people also influenced by the number of people taking a given drug, the dosage and the duration of the prescription, the switch from an older drug to a newer drug, and other factors.

dosage for the various species of animal for which the veterinary medicinal product is intended, its pharmaceutical form, method and route of administration and proposed shelf life;